168 related articles for article (PubMed ID: 37951309)
1. Prurigo nodularis forecast: Light type 2 inflammation with high chances of fibrosis.
Conrad C; Schlapbach C
J Allergy Clin Immunol; 2024 Jan; 153(1):93-94. PubMed ID: 37951309
[No Abstract] [Full Text] [Related]
2. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
[TBL] [Abstract][Full Text] [Related]
3. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
[TBL] [Abstract][Full Text] [Related]
4. Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab.
Ma F; Gharaee-Kermani M; Tsoi LC; Plazyo O; Chaskar P; Harms P; Patrick MT; Xing X; Hile G; Piketty C; Lazzari A; Van Delm W; Maverakis E; Nakamura M; Modlin RL; Kahlenberg JM; Billi AC; Julia V; Krishnaswamy JK; Gudjonsson JE
J Allergy Clin Immunol; 2024 Jan; 153(1):146-160. PubMed ID: 37506977
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
Husein-ElAhmed H; Steinhoff M
J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
[TBL] [Abstract][Full Text] [Related]
7. RNA sequencing reveals the transcriptome profile of the atopic prurigo nodularis with severe itching.
Shao Y; Zhu Y; Xiao Z; Shen Y; Dai B; Tang H; Wang D
Exp Dermatol; 2023 Jan; 32(1):30-40. PubMed ID: 36134503
[TBL] [Abstract][Full Text] [Related]
8. A critical review of dupilumab for adult patients with prurigo nodularis.
Biazus Soares G; Yosipovitch G
Expert Rev Clin Immunol; 2024 Mar; 20(3):249-254. PubMed ID: 37811660
[TBL] [Abstract][Full Text] [Related]
9. A critical evaluation of nemolizumab for prurigo nodularis.
Brooks SG; Yosipovitch G
Expert Rev Clin Immunol; 2024 Jun; 20(6):577-587. PubMed ID: 38217530
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis.
Alkon N; Assen FP; Arnoldner T; Bauer WM; Medjimorec MA; Shaw LE; Rindler K; Holzer G; Weber P; Weninger W; Freystätter C; Chennareddy S; Kinaciyan T; Farlik M; Jonak C; Griss J; Bangert C; Brunner PM
J Allergy Clin Immunol; 2023 Aug; 152(2):420-435. PubMed ID: 37210042
[TBL] [Abstract][Full Text] [Related]
11. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.
Ständer S; Yosipovitch G; Lacour JP; Legat FJ; Paul C; Reich A; Chaouche K; Ahmad F; Piketty C
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1820-1825. PubMed ID: 35766128
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-31 and Pruritic Skin.
Furue M; Furue M
J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33924978
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of biologics in prurigo nodularis.
Müller S; Bieber T; Ständer S
Expert Opin Biol Ther; 2022 Jan; 22(1):47-58. PubMed ID: 34289753
[TBL] [Abstract][Full Text] [Related]
14. Recalcitrant prurigo nodularis treated successfully with dupilumab.
Rambhia PH; Levitt JO
JAAD Case Rep; 2019 May; 5(5):471-473. PubMed ID: 31192991
[No Abstract] [Full Text] [Related]
15. Efficacy of dupilumab in prurigo nodularis in elderly patient.
Giura MT; Viola R; Fierro MT; Ribero S; Ortoncelli M
Dermatol Ther; 2020 Jan; 33(1):e13201. PubMed ID: 31856368
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: Results from a randomised, double-blind, placebo-controlled, phase II/III clinical study in patients aged ≥13 years.
Yokozeki H; Murota H; Matsumura T; Komazaki H;
Br J Dermatol; 2024 Apr; ():. PubMed ID: 38629497
[TBL] [Abstract][Full Text] [Related]
17. Reversal of the disease signature in prurigo nodularis by blocking the itch cytokine.
Sonkoly E
J Allergy Clin Immunol; 2022 Apr; 149(4):1213-1215. PubMed ID: 35189125
[No Abstract] [Full Text] [Related]
18. Resolution of Treatment-Refractory Prurigo Nodularis With Dupilumab: A Case Series.
Wieser JK; Mercurio MG; Somers K
Cureus; 2020 Jun; 12(6):e8737. PubMed ID: 32714676
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
[TBL] [Abstract][Full Text] [Related]
20. Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab.
Deng J; Liao V; Parthasarathy V; Cornman HL; Kambala A; Kwatra MM; Ständer S; Piketty C; Chaskar P; Krishnaswamy JK; Julia V; Kwatra SG
JAMA Dermatol; 2023 Sep; 159(9):977-985. PubMed ID: 37556125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]